’17 differences flagged’: Spurious rabies vaccine racket busted after raids in Delhi
Source Entity
Tabshir Shams
Authorities have uncovered a racket involving counterfeit Abhayrab vaccine vials in Delhi after samples failed potency tests. The manufacturer has denied producing these misbranded units, which exhibited numerous packaging and labeling discrepancies.
Investigation into Counterfeit Rabies Vaccine Racket
The Discovery of Spurious Medical Products
In a significant public health concern, the Central Drugs Laboratory (CDL) in Kasauli, Himachal Pradesh, has officially flagged a batch of the Abhayrab vaccine as 'not of standard quality' (NSG) and 'misbranded.' This discovery followed a targeted enforcement action in April, where Delhi Police and the Drugs Control Department raided an unlicensed residential premises in North Delhi’s Mukherjee Nagar. The operation led to the seizure of vaccine vials bearing batch number KE25012, which, upon rigorous laboratory analysis, failed to meet mandatory potency standards.
Identifying the Counterfeit Markers
Investigators identified approximately 17 distinct differences between the seized vials and genuine reference samples. These discrepancies were not limited to the vaccine's chemical composition but extended to the physical presentation of the product. Forensic analysis revealed blatant errors in packaging, including misspellings such as 'L Posteur' instead of 'L Pasteur,' incorrect punctuation, inconsistent font styles, and deviations in text spacing. Furthermore, the counterfeit vials displayed unauthorized variations in the company’s logo, QR-code verification, and cap color, indicating a sophisticated attempt to mimic a widely trusted medical product.
Implications for Indian Immunologicals and Market Trust
Abhayrab, produced by Indian Immunologicals Ltd (IIL), is a critical component of India’s public health infrastructure, currently commanding nearly 40% of the domestic rabies vaccine market. The manufacturer has categorically denied any involvement in the production of these misbranded vials, asserting that the seized batch did not originate from their facilities. The emergence of such high-volume counterfeit goods threatens to undermine public confidence in essential immunization programs, particularly for a disease like rabies, which requires immediate and effective treatment.
Regulatory Response and Law Enforcement Actions
Following the detection of the fake vaccine, the Central Drug Standards and Control Organisation (CDSCO) has issued an urgent alert to state drug regulators across India. This directive mandates increased vigilance to ensure that no further units from batch KE25012 reach patients. Concurrently, the Delhi Police have arrested four individuals linked to the illicit operation. This coordinated response highlights the ongoing challenge of policing the supply chain for essential biological products against criminal enterprises operating out of residential areas.
Broader Challenges in Pharmaceutical Safety
The incident underscores the persistent vulnerability of the pharmaceutical distribution network to illicit actors. Because rabies vaccines are life-saving interventions, the circulation of non-potent, misbranded products represents a severe threat to patient survival. As regulatory bodies continue their investigations, the case serves as a stark reminder of the necessity for stringent supply chain verification, such as enhanced QR-code authentication and rigorous monitoring of distribution channels, to protect public health from the infiltration of counterfeit medical supplies.
Multiple Citing Sources